Astro-Lab project: Assessment of the safety of long-acting beta agonists (LABAs) in asthma by combining health-care databases and direct patient follow-up: Description of the patient pattern in France and in the United-Kingdom (UK)

E. Van Ganse, The Astro-Lab Group (Lyon, France)

Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease
Session: Treatment and adherence to treatment of respiratory disease
Session type: Thematic Poster Session
Number: 962
Disease area: Airway diseases, Paediatric lung diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
E. Van Ganse, The Astro-Lab Group (Lyon, France). Astro-Lab project: Assessment of the safety of long-acting beta agonists (LABAs) in asthma by combining health-care databases and direct patient follow-up: Description of the patient pattern in France and in the United-Kingdom (UK). Eur Respir J 2013; 42: Suppl. 57, 962

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Long-acting anti-muscarinic agents (LAMA) frequency of use and clinical features of patients with severe asthma in real-life setting: data from the Severe Asthma Network in Italy (SANI) registry
Source: International Congress 2019 – Asthma: outcomes of clinical trials and cohorts
Year: 2019


The DACCORD study: Real-life COPD outpatient treatment with long-acting bronchodilators in Germany
Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease
Year: 2013

A national database study of the effectiveness of switching real-life asthma patients to fostair
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015


REG study: Real-life, longitudinal ICS adherence patterns in a UK asthma population
Source: International Congress 2015 – Management of asthma and other respiratory diseases in primary care
Year: 2015


One-year coverage by inhaled steroids in asthma: French claims data
Source: International Congress 2016 – Asthma: treatment, disease control, and quality of life
Year: 2016

Demographic, clinical and health care resource utilisation characterisation of patients prescribed omalizumab: A retrospective, real world data study
Source: International Congress 2014 – Intervening in allergic asthma
Year: 2014

Characteristics of patients newly prescribed a long acting bronchodilator in the United Kingdom (UK)
Source: International Congress 2014 – Prevalence of COPD and mortality from COPD
Year: 2014

Safety profile of glycopyrronium in patients with COPD: An innovative approach to analyse data from post-marketing surveillance (PMS)
Source: International Congress 2014 – Asthma and COPD management
Year: 2014


An overview of patient adherence to asthma medication in Canada
Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease
Year: 2013

Effectiveness of montelukast on asthma control in infants: A claims data study
Source: International Congress 2015 – Treatment and control of respiratory disease
Year: 2015


LATE-BREAKING ABSTRACT: Profiling of single maintenance and reliever therapy (SMART) dosing instructions of budesonide/formoterol (BFC) in clinical practice
Source: International Congress 2014 – Management of COPD in primary care
Year: 2014


Improvement in asthma control and reduction in medical resource use following treatment with montelukast (PRAACTICAL Study)
Source: Eur Respir J 2005; 26: Suppl. 49, 576s
Year: 2005

Asthma severity, poor control, co-morbidities and prior resource use determined omalizumab prescriptions in a nested case-control study with US claims data
Source: International Congress 2015 – Clincal aspects of asthma: monitoring and mechanisms
Year: 2015


Prevalence of switching from brand to generic asthma medications
Source: International Congress 2015 – Treatment and control of respiratory disease
Year: 2015


Patient characteristics of new initiators of glycopyrronium bromide (GLY) – A multinational, multi-database real-world drug-utilization study
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016


Asthma ICs prescriptions in primary care in France and the United Kingdom: Are they similar?
Source: International Congress 2016 – Asthma management in primary care
Year: 2016


Changes in the treatment of asthma in Spain in the last twenty years. A population based study (ECRHS)
Source: International Congress 2014 – Epidemiology of asthma
Year: 2014


REG endpoint validation: Do SABA prescribing records reliably reflect patient-reported reliever use?
Source: International Congress 2014 – Respiratory symptoms in primary care populations
Year: 2014

Randomized, controlled study of the impact of a mobile health tool on asthma SABA use, control and adherence
Source: International Congress 2016 – Non-inflammatory assessment of airway disorders
Year: 2016

Trends in diagnosis and long-term treatment of patients with asthma in primary health care facilities (1998-2011) in Saint-Petersburg, Russia
Source: Annual Congress 2013 –Treatment and management of asthma in primary care
Year: 2013